trending Market Intelligence /marketintelligence/en/news-insights/trending/6wtss8jvggacdv54w_1g1a2 content esgSubNav
In This List

In latest setback, Santhera's Raxone fails as multiple sclerosis treatment

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


In latest setback, Santhera's Raxone fails as multiple sclerosis treatment

Santhera Pharmaceuticals Holding AG's lead product, Raxone, failed to show any efficacy as a treatment for multiple sclerosis, a neurological disease.

The drug, also known as idebenone, is approved as a treatment of Leber's hereditary optic neuropathy in the European Union. The company has been seeking to expand its intended use, including as a treatment for Duchenne muscular dystrophy which the European Medicines Agency rejected.

The company said patients on Raxone showed no difference in outcome when compared to those that were on placebo in a phase 1/2 trial which was backed by the U.S. National Institutes of Health.

The study included 66 patients that completed the trial.

The Swiss specialty pharmaceutical company's stock price was down 22.44% following the news to CHF20.05 per share as of 8:35 a.m. ET on March 5, 2018.